I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NEfQeHBkgXSxdH;4bYNqfHliYYPzZZk> NXPVcHhuhjFyMDFOwG0> MWfEUXNQ NWL1XYlnUUN3ME2yOkBvVQ>? NGfXNZAzOTl4NEO0NC=>
RS4;11 MnjlZ5l1d3SxeHnjbZR6KGG|c3H5 M4rkTZ4yODBizszN M3S0NGROW09? NEXpSXhKSzVyPUG5NkBvVQ>? MWCyNVk3PDN2MB?=
MOLM13 M4X1UoN6fG:2b4jpZ4l1gSCjc4PhfS=> NE\HbW1,OTByIN88US=> MlvXSG1UVw>? NV;lPWxDUUN3ME2xNlAhdk1? MlrLNlE6PjR|NEC=
NOMO1 NGTwc29kgXSxdH;4bYNqfHliYYPzZZk> MX;+NVAxKM7:TR?= NILZbI1FVVOR MmHDTWM2OD1zNTDuUS=> M4TBcVIyQTZ2M{Sw
HEL MVHjfZRwfG:6aXPpeJkh[XO|YYm= Mn7wglExOCEQvF2= MVrEUXNQ Ml3BTWM2OD1zIN88US=> NVW3eIRkOjF7NkSzOFA>
K562 MmLOZ5l1d3SxeHnjbZR6KGG|c3H5 NXq0cJdLhjFyMDFOwG0> M3n5N2ROW09? MlnqTWM2OD5zMECg{txO MYeyNVk3PDN2MB?=
MEG01 M1:1XYN6fG:2b4jpZ4l1gSCjc4PhfS=> MlvUglExOCEQvF2= MkHJSG1UVw>? M3yyTWlEPTB;MkWg{txO NF\hS5MzOTl4NEO0NC=>
HL60 M1rMdoN6fG:2b4jpZ4l1gSCjc4PhfS=> M3W4eJ4yODBizszN Mn\BSG1UVw>? M{TPVWlEPTB;OEmwJI5O Ml;nNlE6PjR|NEC=
MV4;11 MoLqRZBweHSxc3nzJIF{e2G7 MoXMglExOCEQvF2= NGnsTGhFVVOR NG\0UIRqdmS3Y3XzJIFxd3C2b4Ppdy=> MUGyNVk3PDN2MB?=
MOLM13 M1qwRmFxd3C2b4Ppd{Bie3OjeR?= NVjKRZVFhjFyMDFOwG0> Mk[4SG1UVw>? Mlm3bY5lfWOnczDhdI9xfG:|aYO= M1TDPVIyQTZ2M{Sw
MV4;11 NF\FNoNHfW6ldHnvckBie3OjeR?= MUTEUXNQ M2r2b4Rm[3KnYYPld{B1cGVicnXjdpVqfG2nboSgc4YhSlKGMz:0JIFv\CCrbYDhbZJm\CC{ZXPyeYl1dWWwdDDv[kBETEt7IHHu[EBRSUZzIITvJJRp\SC2cnHud4NzcXC2aX;uZYwhe3SjcoSgd4l1\Q>? NYn6WYpHOjF7NkSzOFA>
PBMC MU\GeY5kfGmxbjDhd5NigQ>? MUHEUXNQ MmK2bY5pcWKrdIOgTWwuPiC5aYToJJBKSzVyIH;mJFYvPw>? MknuNlI1OzdzMUW=
A2 NFrFVGpHfW6ldHnvckBie3OjeR?= NEW2O2h,OTBizszN M3PhO2ROW09? NV3mU3ZLemWjY4TpeoF1\XNibHH0[Y51KEiLVj2x NX\TS3Y5OjN{NUWyNVg>
A72 NYru[GlmTnWwY4Tpc44h[XO|YYm= Mkm2glExKM7:TR?= NHPvUVRFVVOR MkizdoVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z NIrDeHUzOzJ3NUKxPC=>
BC1 M{HnPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3vzdp4yKM7:TR?= NXX4RnNETE2VTx?= NX7MVY9kUUN3ME2yNlAhdk1? MmL4NlM4QTJ2NEi=
BC3 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoHTglEh|ryP MY\EUXNQ M1\YdGlEPTB;NE[wJI5O Mn20NlM4QTJ2NEi=
BCBL1 MoTJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLsVm9zhjFizszN MmrWSG1UVw>? NXHDdVRqUUN3ME2zN|Ahdk1? MWWyN|c6OjR2OB?=
BJAB M{LBc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXXGU3hThjFizszN NVHrc2p2TE2VTx?= MnnETWM2OD17N{Cgcm0> M{XxOVI{Pzl{NES4
Namalwa MkHCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVz+NUDPxE1? NEPTeXFFVVOR MkWyTWM2OD17N{Cgcm0> NI\3NGIzOzd7MkS0PC=>
Jurkat MoXzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NITGZ5J,OSEQvF2= MXnEUXNQ MmrPTWM2OD1zMkKwJI5O NVTENGREOjN5OUK0OFg>
MM1S NFfnZYlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVT+NUDPxE1? MUjEUXNQ MWPJR|UxRTd4MDDuUS=> NXPOZm9EOjN5OUK0OFg>
U266 M1\N[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{nlTJ4yKM7:TR?= NGmzS|JFVVOR NHm0d5dKSzVyPUm1NEBvVQ>? NU\xN3NoOjN5OUK0OFg>
UM-PEL-1 M2\FXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2j2TJ4yKM7:TR?= MnTYSG1UVw>? MnnmTWM2OD1{MUCgcm0> MnzuNlM4QTJ2NEi=
UM-PEL-3 MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX3+NUDPxE1? MWHEUXNQ MYjJR|UxRTF6MDDuUS=> NGHxbZIzOzd7MkS0PC=>
BC1 MYrGeY5kfGmxbjDhd5NigQ>? NWjqWJZpPTByIH7N M1;KfmROW09? NIrueWRqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 NWTXeY9[OjN5OUK0OFg>
BC3 MmLnSpVv[3Srb36gZZN{[Xl? MnrvOVAxKG6P NXroV|cxTE2VTx?= M1q2eIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= MWOyN|c6OjR2OB?=
BC1 NXPjS|VKTnWwY4Tpc44h[XO|YYm= MXK4NFAhdk1? M1vOR2ROW09? NYH1c49[emWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? M1;0V|I{Pzl{NES4
BC3 NV7MOHJvTnWwY4Tpc44h[XO|YYm= M4i3cFgxOCCwTR?= NHH3[YhFVVOR M1HrZpJm\HWlZYOgZ{1OgWNicILveIVqdiCuZY\lcJM> Ml:1NlM4QTJ2NEi=
H929 NXfIVFMzTnWwY4Tpc44h[XO|YYm= NXriNYhOhjFizszN M{fzWWROW09? MnTlbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NXzkfo1uOjR|M{W0PVk>
KMS12PE M4rmeGZ2dmO2aX;uJIF{e2G7 MVH+NUDPxE1? NW\RPWh5TE2VTx?= NFrNeZJqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MonlNlQ{OzV2OUm=
KMS12BM MlfBSpVv[3Srb36gZZN{[Xl? NVnJbVFEhjFizszN MXTEUXNQ NXjOTXVbcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MYeyOFM{PTR7OR?=
KMS18 MWXGeY5kfGmxbjDhd5NigQ>? MUH+NUDPxE1? M1K3[mROW09? M1zpUYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NU\YS|EzOjR|M{W0PVk>
KMS11 NILPdJRHfW6ldHnvckBie3OjeR?= NVrxb4pvhjFizszN MVXEUXNQ M2rNRolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MU[yOFM{PTR7OR?=
RPMI8226 NHPlNWxHfW6ldHnvckBie3OjeR?= NH;Fe5Z,OSEQvF2= MYDEUXNQ MV7pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NGfVPGczPDN|NUS5PS=>
H929 MUDBdI9xfG:|aYOgZZN{[Xl? NHfQR29,OSEQvF2= NGX3UJRFVVOR MknLbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUOyOFM{PTR7OR?=
KMS12PE Mo\BRZBweHSxc3nzJIF{e2G7 MnzrglEh|ryP NEXnZ3ZFVVOR NXvObFNbcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Moj0NlQ{OzV2OUm=
KMS12BM M3vxTWFxd3C2b4Ppd{Bie3OjeR?= MY\+NUDPxE1? MW\EUXNQ MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NIXBXJAzPDN|NUS5PS=>
KMS18 NIi3dVZCeG:ydH;zbZMh[XO|YYm= MUj+NUDPxE1? NUT6ZXJ{TE2VTx?= NFfNcYJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MX6yOFM{PTR7OR?=
KMS11 M174PWFxd3C2b4Ppd{Bie3OjeR?= MWX+NUDPxE1? NXLCXXV6TE2VTx?= NHrMOoFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2S0N|I1OzN3NEm5
RPMI8226 MU\BdI9xfG:|aYOgZZN{[Xl? MkHsglEh|ryP M{HiUWROW09? NUf6XZM6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUGyOFM{PTR7OR?=
U87MG MW\GeY5kfGmxbjDhd5NigQ>? NUjPNmJphjFyIN88US=> M1\4PWROW09? MnfydoVlfWOnczDVPFdOTyClZXzseYxieiCDVGCge4l1cCCLQ{WwJI9nKDFwMEWg{txO Mn[3NlQ1QTZ|OEG=
A172 M2[0[2Z2dmO2aX;uJIF{e2G7 NEfPU2F,OTBizszN MnXRSG1UVw>? MV7y[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6yPEDPxE1? MV[yOFQ6PjN6MR?=
SW1783 MmS3SpVv[3Srb36gZZN{[Xl? MnfaglExKM7:TR?= MkXwSG1UVw>? NFLOflFz\WS3Y3XzJINmdGy3bHHyJGFVWCC5aYToJGlEPTBib3[gNk43QCEQvF2= MXmyOFQ6PjN6MR?=
U87MG M37BVGZ2dmO2aX;uJIF{e2G7 Ml30glExKM7:TR?= MoHKSG1UVw>? NF3qUlFqdmO{ZXHz[ZMheHKxcH;yeIlwdiCxZjDj[YxteyCrbjD0bIUhTzFxUzD0doFve2m2aX;u MUSyOFQ6PjN6MR?=
RAW267.4 MWDGeY5kfGmxbjDhd5NigQ>? NXi5dVZzOSEQvF2= MlPmSG1UVw>? MYjy[YR2[2W|IFnMMVYheHKxZIXjeIlwdiCrbnT1Z4VlKGK7IFzQVy=> M1ewPVI1QDV7MEC4
RAW267.4 M3:wbGZ2dmO2aX;uJIF{e2G7 M{nJR|Eh|ryP M4PMS2ROW09? M2PIc5Jm\HWlZYOgeIhmKGG|c3;jbYF1cW:wIHLleJdm\W5iQmLEOEBidmRiYXPleJlt[XSnZDDwOlU> NWrkPW57OjR6NUmwNFg>
Me007 NGfoPYxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NITBPFJ,OTByIN88US=> NX3TTlJYTE2VTx?= M{WwRolvcGmkaYTzJJRp\SCpcn;3eIg> NUjsOWZFOjR7ME[xN|c>
SK-Mel-28 NEfk[pdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlfSglExOCEQvF2= M3fMWWROW09? M1rjbYlvcGmkaYTzJJRp\SCpcn;3eIg> M4\MeVI1QTB4MUO3
Mel-RMU MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVT+NVAxKM7:TR?= NHTXd5NFVVOR NFHCNYxqdmirYnn0d{B1cGViZ4Lve5Rp NVzBVJY1OjR7ME[xN|c>
Mel-JD NHjSVXNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGXTbGx,OTByIN88US=> NWP4SmtXTE2VTx?= MUPpcohq[mm2czD0bIUh\3Kxd4To NX3ZXlA{OjR7ME[xN|c>
Mel-RM NV74cVJET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH7i[3p,OTByIN88US=> MV3EUXNQ MWDpcohq[mm2czD0bIUh\3Kxd4To NHzFUHMzPDlyNkGzOy=>
Me007 M122c2Fxd3C2b4Ppd{Bie3OjeR?= MXv+NVAxKM7:TR?= NXfmRYx3TE2VTx?= M1i3c4lv\HWlZYOgZZBweHSxc3nz NFjpcWMzPDlyNkGzOy=>
SK-Mel-28 NWe5fVRTSXCxcITvd4l{KGG|c3H5 MlnZglExOCEQvF2= MUXEUXNQ NHvQT3NqdmS3Y3XzJIFxd3C2b4Ppdy=> MUiyOFkxPjF|Nx?=
Mel-RMU NFnrUJRCeG:ydH;zbZMh[XO|YYm= MmHlglExOCEQvF2= MmXrSG1UVw>? NIfuSXVqdmS3Y3XzJIFxd3C2b4Ppdy=> MXiyOFkxPjF|Nx?=
Mel-JD MVjBdI9xfG:|aYOgZZN{[Xl? NG\ZZpR,OTByIN88US=> M2T6UGROW09? NHfWfYlqdmS3Y3XzJIFxd3C2b4Ppdy=> M{HNUFI1QTB4MUO3
Mel-RM M37McWFxd3C2b4Ppd{Bie3OjeR?= M4jLcZ4yODBizszN NEn3cJNFVVOR NXu5d29icW6mdXPld{BieG:ydH;zbZM> MlPjNlQ6ODZzM{e=
Me007 M2P4cmZ2dmO2aX;uJIF{e2G7 M4nHbFExKM7:TR?= NITnZodFVVOR NXfEWXRlcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz NHTt[mozPDlyNkGzOy=>
SK-Mel-28 NGf4N|hHfW6ldHnvckBie3OjeR?= MYCxNEDPxE1? MUTEUXNQ NWT4cItbcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz NF\VPG4zPDlyNkGzOy=>
Mel-RMU MoLjSpVv[3Srb36gZZN{[Xl? M1vWXFExKM7:TR?= MoDkSG1UVw>? M4DoWIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NGfxPFEzPDlyNkGzOy=>
Mel-JD MXzGeY5kfGmxbjDhd5NigQ>? NXizTWZIOTBizszN MkHWSG1UVw>? NYTYbJVPcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz MX[yOFkxPjF|Nx?=
Mel-RM NETwRohHfW6ldHnvckBie3OjeR?= M4Pwd|ExKM7:TR?= NVzJZ4VVTE2VTx?= NXjsd5NDcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz MmLRNlQ6ODZzM{e=
Me007 Ml\KSpVv[3Srb36gZZN{[Xl? NWS1PINJOTBizszN M13rbmROW09? NGnQTG92eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NGjKenozPDlyNkGzOy=>
SK-Mel-28 NGrKVXJHfW6ldHnvckBie3OjeR?= NWPJV|ZNOTBizszN Mlv6SG1UVw>? MVL1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| NHPtPGEzPDlyNkGzOy=>
Mel-RMU NVW4W5J1TnWwY4Tpc44h[XO|YYm= NXW0b5QzOTBizszN MV;EUXNQ M1fBNZVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NFP0cFkzPDlyNkGzOy=>
Mel-JD MUfGeY5kfGmxbjDhd5NigQ>? MUSxNEDPxE1? MUjEUXNQ Mn;ueZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= M33hSVI1QTB4MUO3
Mel-RM MX3GeY5kfGmxbjDhd5NigQ>? MXmxNEDPxE1? NFi5VI1FVVOR NIK5eoJ2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NVS1PWliOjR7ME[xN|c>

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID